Maël VINCENT

CTO

📍 France🔄 Updated September 2026💼 5 investments📅 3 years investing🗓 Last invested Nov 2024
Operator-angel🌍 France
5
Total investments
1
Early stage
3
Mid stage
1
Late stage
3y
Years active

Portfolio

5 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Private Investor
Nov 2024
Lauréat France 2030 "Réacteurs Nucléaires Innovants" HEXANA est une startup essaimée du CEA qui conçoit un réacteur nucléaire modulaire à neutrons rapides refroidi au sodium. HEXANA construit la solution énergétique crédible, soutenable, compétitive et bas-carbone pour sortir durablement des énergies fossiles..
early stageManufacturing
Private Investor
Oct 2024
Biomemory is a deep-tech company specialized in enterprise data storage. It leverages molecular engineering to build cost-effective and energy-efficient exabyte rackable appliances for Data Centers. Biomemory also develops high-quality DNA-based anti-counterfeiting systems with minimal ecological impact. Contact us: contact@biomemory.com Jobs and internships: jobs@biomemory.com
mid stageBiotechnology
Private Investor
May 2024
Aujourd’hui, 25% de lempreinte carbone mondiale provient des échanges internationaux : ils génèrent énormément d’émissions pour trop peu d’actions mises en place. Keewe, c’est la fintech pour des échanges internationaux plus simples et plus durables. On pense que l’action écologique ne doit pas être un coût à subir mais un avantage compétitif pour embarquer les entreprises. On agit sur - l’impact : on mesure l’empreinte carbone des opérations tout en générant de l’impact positif - le prix : on est ultra compétitifs et transparents par rapport au marché bancaire et aux autres fintech - la simplicité : c’est facile, intuitif. Tous les services financiers internationaux sont au même endroit. Pour convaincre, on doit simplifier. L’impact ne doit pas être une charge supplémentaire. Les entreprises n’ont rien à faire: on est là pour accompagner. ____________________________________________________________________________ Lauréat de Scale up Excellence de la French Tech Prix coup de ❤ du Challenge Fintech for Tomorrow 2019 Labellisé Envol! : https://www.envol-entreprise.fr/ Et accéléré par WILCO (https://www.wilco-startup.com/) www.keewe.eu
Private Investor
Apr 2024
Ziwig Biotech is a biotechnology company pioneering the analysis of salivary RNA and the application of artificial intelligence to biomolecular biology. At the crossroads of medicine, data science, and digital technology, Ziwig develops non-invasive tests and therapeutic biomarkers designed to transform the diagnosis and management of chronic diseases—particularly those affecting women. Its flagship innovation, Endotest®, is the first non-invasive and highly reliable saliva-based test for the diagnosis of endometriosis. This breakthrough innovation, multiple award-winner (Galien Prize, Tech For Future Award), exemplifies Ziwig’s ability to revolutionize women’s health through the convergence of biotechnology, artificial intelligence, and precision medicine. Ziwig operates at the heart of a rapidly evolving global health ecosystem, where universal access to diagnosis and prevention is a major challenge for equity and sustainability. Through its scientific and societal commitment, Ziwig contributes to building a more human, accessible, and universal precision medicine—serving patients, healthcare professionals, and the health systems of the future. 🌐 www.ziwig.com
Private Investor
Apr 2023
Substack is a new media app that connects you with the creators, ideas, and communities you care about most. Founded in 2017, Substack is building a new economic engine for culture by putting publishers in charge and enabling subscribers to support the work they deeply value. There are more than 5 million paid subscriptions to writers and creators across the Substack network.
Experience · 6 entries
All (6)
Investments (5)
Founder (1)
2024
Private Investor
Nov 2024
Lauréat France 2030 "Réacteurs Nucléaires Innovants" HEXANA est une startup essaimée du CEA qui conçoit un réacteur nucléaire modulaire à neutrons rapides refroidi au sodium. HEXANA construit la solution énergétique crédible, soutenable, compétitive et bas-carbone pour sortir durablement des énergies fossiles..
early stageManufacturing
Private Investor
Oct 2024
Biomemory is a deep-tech company specialized in enterprise data storage. It leverages molecular engineering to build cost-effective and energy-efficient exabyte rackable appliances for Data Centers. Biomemory also develops high-quality DNA-based anti-counterfeiting systems with minimal ecological impact. Contact us: contact@biomemory.com Jobs and internships: jobs@biomemory.com
mid stageBiotechnology
Private Investor
May 2024
Aujourd’hui, 25% de lempreinte carbone mondiale provient des échanges internationaux : ils génèrent énormément d’émissions pour trop peu d’actions mises en place. Keewe, c’est la fintech pour des échanges internationaux plus simples et plus durables. On pense que l’action écologique ne doit pas être un coût à subir mais un avantage compétitif pour embarquer les entreprises. On agit sur - l’impact : on mesure l’empreinte carbone des opérations tout en générant de l’impact positif - le prix : on est ultra compétitifs et transparents par rapport au marché bancaire et aux autres fintech - la simplicité : c’est facile, intuitif. Tous les services financiers internationaux sont au même endroit. Pour convaincre, on doit simplifier. L’impact ne doit pas être une charge supplémentaire. Les entreprises n’ont rien à faire: on est là pour accompagner. ____________________________________________________________________________ Lauréat de Scale up Excellence de la French Tech Prix coup de ❤ du Challenge Fintech for Tomorrow 2019 Labellisé Envol! : https://www.envol-entreprise.fr/ Et accéléré par WILCO (https://www.wilco-startup.com/) www.keewe.eu
Private Investor
Apr 2024
Ziwig Biotech is a biotechnology company pioneering the analysis of salivary RNA and the application of artificial intelligence to biomolecular biology. At the crossroads of medicine, data science, and digital technology, Ziwig develops non-invasive tests and therapeutic biomarkers designed to transform the diagnosis and management of chronic diseases—particularly those affecting women. Its flagship innovation, Endotest®, is the first non-invasive and highly reliable saliva-based test for the diagnosis of endometriosis. This breakthrough innovation, multiple award-winner (Galien Prize, Tech For Future Award), exemplifies Ziwig’s ability to revolutionize women’s health through the convergence of biotechnology, artificial intelligence, and precision medicine. Ziwig operates at the heart of a rapidly evolving global health ecosystem, where universal access to diagnosis and prevention is a major challenge for equity and sustainability. Through its scientific and societal commitment, Ziwig contributes to building a more human, accessible, and universal precision medicine—serving patients, healthcare professionals, and the health systems of the future. 🌐 www.ziwig.com
2023
Private Investor
Apr 2023
Substack is a new media app that connects you with the creators, ideas, and communities you care about most. Founded in 2017, Substack is building a new economic engine for culture by putting publishers in charge and enabling subscribers to support the work they deeply value. There are more than 5 million paid subscriptions to writers and creators across the Substack network.
Show all 6 entries ↓
Investment activity
2023–2024 · 5 investments
2023120244
Recent (last 2 years)Earlier